🔍 Observations
Topline
- Revenue surged 27.3% YoY to ₹48,190.59 Mn (FY26 vs ₹37,866.91 Mn FY25), reflecting strong EMS demand across customer verticals.
- Q4FY26 revenue of ₹14,650.12 Mn grew 58.5% YoY vs Q4FY25 (₹9,243.61 Mn), accelerating meaningfully from the prior quarter’s ₹12,641.80 Mn.
- Other income fell to ₹378.07 Mn (FY26) from ₹489.22 Mn (FY25), confirming topline quality is operationally driven.
Bottomline
- PAT nearly doubled to ₹3,458.06 Mn (FY26) from ₹1,844.50 Mn (FY25) — an 87.5% YoY jump, materially outpacing revenue growth.
- Effective tax rate rose to 22.4% (FY26) vs 22.2% (FY25), broadly stable — PAT expansion is earnings-driven, not tax-distorted.
- Basic EPS grew 77.4% YoY to ₹16.94 from ₹9.55, despite equity dilution from the QIP; underlying earnings power per share strengthened sharply.
Margins
- EBITDA (PBT + Finance costs + D&A): FY26 = ₹4,453.76 + ₹482.60 + ₹841.09 = ₹5,777.45 Mn; EBITDA margin = 5,777.45 / 48,190.59 = 12.0% vs FY25 = (₹2,370.75 + ₹584.60 + ₹750.69) / ₹37,866.91 = 9.8% — 220 bps expansion.
- Net profit margin: ₹3,458.06 / ₹48,190.59 = 7.2% (FY26) vs ₹1,844.50 / ₹37,866.91 = 4.9% (FY25) — 230 bps expansion.
- Finance costs declined to ₹482.60 Mn (FY26) from ₹584.60 Mn (FY25) despite balance sheet growth, signalling working capital discipline improving.
Growth Trajectory
- 27.3% revenue CAGR on a ₹37.9 Bn base is high-quality for EMS; Q4FY26’s 58.5% YoY print suggests deal wins ramping in H2.
- PAT growth of 87.5% YoY indicates operating leverage is kicking in — fixed cost absorption improving as scale rises.
- ROE held steady at 12.3% despite significant equity dilution (QIP proceeds of ₹9,781.92 Mn), implying the capital is being deployed productively.
🧮 Profit & Loss Statement
🧮 Balance Sheet
🧮 Cash Flows Statement
🟢 Green Flags
- 87.5% PAT growth on 27.3% revenue growth signals emerging operating leverage — fixed-cost base is being scaled efficiently.
- EBITDA margin expansion of ~220 bps to 12.0% demonstrates pricing discipline and cost control at the gross level.
- Finance costs down 17.5% YoY despite asset growth — net debt reduced sharply post-QIP, cutting interest burden.
- QIP of ₹9,781.92 Mn strengthens the balance sheet ahead of capex cycles; equity now dominates the funding mix.
- Q4FY26 revenue at ₹14,650 Mn — highest ever quarterly print — validates strong order pipeline execution.
- OCF doubled to ₹2,895.65 Mn from ₹1,764.63 Mn — cash generation is accelerating in line with earnings.
- Current borrowings fell sharply to ₹3,138.23 Mn from ₹5,493.15 Mn — working capital funding stress is easing.
🔴 Red Flags
- Trade receivables up 24.6% to ₹18,407.77 Mn vs revenue growth of 27.3% — DSO broadly in line, but absolute receivables quantum (38% of revenue) remains high for an EMS company.
- Inventories grew 29.2% to ₹10,616.02 Mn, outpacing revenue growth — potential component stockpiling risk if demand softens.
- Goodwill jumped to ₹4,546.53 Mn from ₹3,221.03 Mn (+41.2%), linked to the ₹2,350 Mn subsidiary investment — acquisition quality and integration risk not yet visible.
- FCF negative: OCF ₹2,895.65 Mn less capex ₹1,835.10 Mn + ₹82.49 Mn = FCF of ~₹978 Mn, thin relative to reported PAT of ₹3,458 Mn — PAT-to-FCF conversion at ~28%, a meaningful gap.
- Trade payables at ₹19,585.65 Mn (MSME + others) fund much of the working capital cycle — payable-stretching dependency is a structural risk if vendor terms tighten.
- Other expenses surged 37.9% YoY to ₹4,699.39 Mn, growing faster than revenue — composition needs monitoring for one-off vs structural cost creep.
- ROE at 12.3% is marginally lower than FY25’s 12.5% despite PAT doubling — equity base expanded faster than earnings due to QIP, diluting near-term return ratios.
📊 Balance Sheet Analysis
- Equity-heavy post-QIP: Total equity at ₹30,654.69 Mn vs total debt (current + non-current borrowings) of ₹3,531.17 Mn — net debt is effectively negligible; D/E ~0.12x.
- Working capital intensity is high: Inventories + receivables = ₹29,023.79 Mn vs trade payables of ₹19,585.65 Mn — net working capital of ~₹9,438 Mn absorbed by operations; EMS structurally demands this but the quantum is watch-worthy.
- Goodwill + intangibles at ₹4,754.36 Mn are 16.5% of total equity — acquisition-led intangibles not yet earnings-tested; impairment risk if acquired entities underperform.
- Current ratio: Current assets ₹41,496.86 Mn / Current liabilities ₹24,408.57 Mn = 1.70x — adequate liquidity buffer; short-term solvency not a concern.
💰 Cash Flow Analysis
- OCF of ₹2,895.65 Mn (vs ₹1,764.63 Mn FY25) reflects genuine earnings quality improvement, with trade payable expansion of ₹3,754.68 Mn partly subsidising the working capital cycle.
- Capex of ₹1,917.59 Mn (tangible + intangible) and a ₹2,350 Mn subsidiary investment drove net investing outflow of ₹7,419.60 Mn — growth mode is clearly on; asset base is being actively built.
- QIP proceeds of ₹9,781.92 Mn funded the investing outflow and allowed simultaneous debt reduction of ₹3,010.56 Mn in current borrowings — a structurally positive capital allocation sequence.
- FCF (~₹978 Mn) vs PAT (₹3,458 Mn) — conversion of ~28% indicates working capital consumption and capex are absorbing most earnings; FCF improvement is the key metric to track in FY27.
💡 Investment Outlook
Syrma SGS delivered a strong FY26 — near-doubling of PAT, 220 bps margin expansion, and meaningful debt reduction post-QIP — validating its EMS scale-up thesis.
The balance sheet is conservatively funded, and operating leverage is beginning to show. However, the PAT-to-FCF conversion gap (~28%), rising goodwill from acquisitions, and the high working capital intensity of the business model warrant close monitoring.
Investors should track receivables quality, acquisition integration outcomes, and FCF conversion as the primary indicators of whether FY27 sustains this trajectory.
Disclaimer: This post features ChartAlert-AI-generated financial content which may contain inaccuracies or errors. This commentary is strictly for informational purposes and does not constitute a recommendation to buy or sell any security. Investors are responsible for performing their own due diligence; always consult with a licensed financial advisor before making investment decisions.
Beyond the Price Action: Fundamental Analysis is Coming to ChartAlert
ChartAlert is evolving into integrated research with a future update that will embed fundamental data into your workflow. Alongside technical analysis, the new release will allow access to financial data, quarterly results review, earnings call transcripts, and valuation tools, connecting price action with corporate performance for smarter, data‑driven decisions.